Research
Hormonal
Dual GIP/GLP-1 receptor agonists (e.g., tirzepatide) produce greater body weight reduction than selective GLP-1 receptor agonists.
Tirzepatide, a dual-acting drug, is more effective for weight loss than standard GLP-1 drugs, achieving up to 21% weight loss in trials. It is taken once weekly, starting at a low dose to minimize stomach upset.
StrongSupportsVERY_HIGH confidence
there are now several dual GIP/GLP-1 receptor agonists in clinical development, including tirzepatide... One of the more recent representatives of this drug class, and the one that has been shown to exert a superior effect to GLP-1 receptor agonists in humans, is LY3298176/tirzepatide
Why this rating
Based on Phase III trials (SURPASS programme) and regulatory approval.
Source
Gut hormone-based pharmacology: novel formulations and future possibilities for metabolic disease therapy
Matthias H. Tschöp et al. · Diabetologia · 2023
narrative_reviewCited 80×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →